{"id":399186,"date":"2025-05-25T01:05:00","date_gmt":"2025-05-24T23:05:00","guid":{"rendered":"https:\/\/medizinonline.com\/citocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos\/"},"modified":"2025-05-24T23:00:42","modified_gmt":"2025-05-24T21:00:42","slug":"citocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/citocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos\/","title":{"rendered":"Citocinas Th2 em foco: pontos de ataque comprovados e novos"},"content":{"rendered":"\n<p><strong>A gama de terapias com anticorpos para a dermatite at\u00f3pica (DA) expandiu-se mais uma vez na Europa. Para al\u00e9m do dupilumab e do tralokinumab, o lebrikizumab \u00e9 outro produto biol\u00f3gico dispon\u00edvel neste pa\u00eds que interv\u00e9m especificamente na cascata inflamat\u00f3ria e tem um perfil de seguran\u00e7a impressionante. Na UE, o nemolizumab foi tamb\u00e9m recentemente autorizado para a DA.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fcitocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>A gama de terapias com anticorpos para a dermatite at\u00f3pica (DA) expandiu-se mais uma vez na Europa. Para al\u00e9m do dupilumab e do tralokinumab, o lebrikizumab \u00e9 outro produto biol\u00f3gico&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fcitocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":399188,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Produtos biol\u00f3gicos para a dermatite at\u00f3pica  ","footnotes":""},"category":[11344,11356,11521,11453,11529,11551],"tags":[65601,82410,82409,12217,82407,12492,13525,16238,82408,82406,65865,13302],"powerkit_post_featured":[],"class_list":["post-399186","post","type-post","status-publish","format-standard","has-post-thumbnail","category-alergologia-e-imunologia-clinica","category-dermatologia-e-venereologia-pt-pt","category-estudos","category-farmacologia-e-toxicologia","category-relatorios-do-congresso","category-rx-pt","tag-adtralza-pt-pt","tag-advogado","tag-arcadia-pt-pt","tag-biologicos","tag-citocinas-th2","tag-dermatite-atopica","tag-dupilumab-pt-pt","tag-dupixent-pt-pt","tag-ebglyss-pt-pt","tag-lebrikizumab-pt-pt","tag-nemolizumab-pt-pt","tag-tralokinumab-pt-pt","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 23:29:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":399195,"slug":"citocinas-th2-en-el-punto-de-mira-puntos-de-ataque-probados-y-nuevos","post_title":"Citocinas Th2 en el punto de mira: puntos de ataque probados y nuevos","href":"https:\/\/medizinonline.com\/es\/citocinas-th2-en-el-punto-de-mira-puntos-de-ataque-probados-y-nuevos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/399186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=399186"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/399186\/revisions"}],"predecessor-version":[{"id":399189,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/399186\/revisions\/399189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/399188"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=399186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=399186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=399186"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=399186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}